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Summary 
47 patients were involved in the research. The use of immune response modifi er glucosaminilmuramilpentapeptide 
(LIASTEN) along with the  antimycobacterial therapy resulted in speeding up abacillation  in (1.7±0.2) months, disper-
sion of focal abnormalities and infi ltration in (1.5±0.1) months and the cicatrization of destruction cavities in (1.6±0.1) 
months as compared to the previous indicators. It should be noted that the average treatment duration during the intensive 
phase might be reduced by (1.9±0.3) months. 
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Rezumat
În acest studiu au fost implicați 47 de pacienți. A fost administrat imunomadulatorul glucosaminilmuramilpentapeptid 
(LIASTEN) în complex cu tratamentul antituberculos, care a contribuit la accelerarea abacilării în (1,7 ± 0,2) luni, re-
zorbția focarelor infi ltrative în (1,5 ± 0,1) luni și cicatrizarea cavităților destructive  на(1,6 ± 0,1) față de lotul de control. 
Rezultatele obținute au dat posibilitate de a reduce durata medie a tratamentului în faza intensivă cu 1,9 ± 0,3 luni.
Cuvinte cheie. Tuberculoza cu multirezistență, glucosaminilmuramilpentapeptidul, efi cacitatea tratamentului.
Резюме 
В настоящее исследование включены 47 пациентов, у которых был использован иммуномодулятор глюкоза-
минилмурамилпентапептид (LIASTEN) вместе  с антибактериальной терапией, что определило  ускорение аба-
циллирования  на (1,7 ± 0,2) мес., рассасывание очаговых изменений и инфильтрации на (1,5 ± 0,1) мес. и зажив-
ление каверн на  (1,6 ± 0,1) мес., в сравнении с контрольной группой, которые получали только антибактериаль-
ные препараты. Это дало возможность сократить длительность лечения в интенсивной фазе  на    (1,9 ± 0,3)  мес. 
Кдючевые слова. Туберкулез с множестенной лекарстенной резистентностью, глюкозаминилмурамилпен-
тапептид, эффективность лечения.
The follow-up of drug resistant tuberculosis pro-
fi le, prevalence and incidence  in Ukraine, the spread 
of drug resistant forms of the specifi c process, in par-
ticular, multi-drug resistant being the most dangerous 
one causing the loss of labour capacity, health deteri-
oration as well as the increase of disability and mor-
tality rates have been the topical issues nowadays [4, 
7, 10, 14, 15].
The favourable conditions for the selection of 
drug resistant tuberculosis mycobacteria are one of 
the reasons for the multi-drug resistant tuberculosis 
epidemy: the lack of full controlled cure, treatment 
interruptions, poor sequestration in in-patient depart-
ments (nosocomial contamination) etc [1]. 
The curing of patients diagnosed with multi-drug 
resistant and extensively drug-resistant tuberculosis 
is very challenging and differs from the treatment of 
patients releasing mycobacteria sensitive to antituber-
culosis drugs according to chemical therapy regimes 
and the relevant agents included in this therapy, the 
treatment duration and the frequency of undesired 
side effects. Thus, the treatment codes applied for 
chemical resistant tuberculosis [3, 11 - 13] have been 
constantly improved over the last years. 
For this purpose, the differentiated use of patho-
genetic agents have been developed for increasing the 
effi ciency of complex chemical therapy for treating 
tuberculosis along with the search of new etiotropic 
therapy codes [8]. 
LIASTEN serving as a pathogenetic agent in the 
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complex therapy was prescribed in cases of respira-
tory diseases, the fi rst diagnosed chemical sensitive 
tuberculosis [2, 5,], breast cancer [9], surgical infec-
tions [6] etc. Taking into consideration the necessity 
of raising the treatment effi ciency of multi-drug resis-
tant tuberculosis a research has been made to prove 
the reasonability of prescribing immune response 
modifi er glucosaminilmuramilpentapeptide (LIAS-
TEN). 
The study the effi ciency of the immune response 
modifi er glucosaminilmuramilpentapeptide (LIAS-
TEN) used in the complex therapy for treating multi-
drug resistant tuberculosis based on some clinical, 
roentgenographical and laboratory research is the 
objective of this scientifi c paper.
Materials and methods. 47 patients took part in 
the research. The immune response modifi er glucos-
aminilmuramilpentapeptide (LIASTEN) serving as 
a pathogenetic agent was used in combination with 
the antimycobacterial therapy (AMBT). The patients 
were divided into two groups: the 1st group consist-
ed of 22 patients undergoing only antimycobacterial 
therapy (AMBT); the 2nd one consisted of 25 people 
undergoing the complex treatment involving LIAS-
TEN (with the following treatment code: AMBT+LI-
ASTEN). All the patients underwent the complex clin-
ical roentgenographical, microbiological and general 
laboratory examination in the intensive phase (before 
curing, in 2, 4, 6 and 8 months after treatment). The 
antimycobacterial therapy was applied in accordance 
with the drug sensitivity test in the generally accepted 
doses with a view to kg-BM (basic treatment).
LIASTEM is an immune response modifi er of 
natural origin with a wide spectrum of effect. It is a 
fragment of the lactic bacteria cell wall with the glu-
cosaminilmuramilpentapeptide as an active substance 
(N- acetylglucosaminyl-N-acetylmuramil-L-al-
anyl-D-glutamyl-L-lysyl-D-alanyl-L-asparagile) 
with regard to peptides. LIASTEN was injected intra-
muscularly in cases of evident T-cell immunological 
suppression with over 30.0% decrease of T-lympho-
cytic pool once per 6 days, No. 5.
Intoxication decrement, the dispersion of focal 
abnormalities and infi ltration in the lungs, cicatriza-
tion of destruction cavities, abacillation and the nor-
malization of general laboratory parameters in the 
course of intensive therapy were the main criteria of 
effi cient tuberculosis treatment. 
Findings and discussion. The division of pa-
tients according to clinical forms and the evidence of 
destruction in the lung tissue as well as the treatment 
methods are shown in Table 1.
As the Table 1 shows, the groups under research 
were practically identical according to the clinical 
forms, the evidence of lung tissue destruction and the 
structure of pathogen’s resistance to antimycobacte-
rial agents. All the patients were fi rst diagnosed with 
multi-drug resistant pulmonary tuberculosis. The fre-
quency of the confi rmed infi ltrative and disseminated 
forms of the specifi c process was almost the same in 
all the groups. 
Table 1
The division of patients diagnosed with multi-drug 
resistant tuberculosis according to clinical forms, 




The 1st group 
(antimycobacterial 
therapy)
The 2nd group  anti-
mycobacterial ther-
apy + LIASTEN)
total destruction(abs./ %) total
Destruction 
(abs./ %)
Infi ltrative 10 10 (100.0) 7 7 (100.0)
Disseminated 12 12 (100.0) 8 8 (100.0)
total   - n






   100.0
The research proved that the toxic syndrome in 
cases of LIASEN prescribed at the early stage of 
antimycobacterial therapy for patients diagnosed 
with multi-drug resistant tuberculosis (the 2nd group) 
was interrupted 1.6 times more frequently and faster 
as compared to the fi rst group (68.0% versus 40.9% 
р<0.05). Intoxication syndrome were completely 
interrupted in the 2nd group during the fi rst four 
months. 
The same tendency was also evident in the general 
laboratory parameters. 
Table 2
Frequency and terms of intoxication syndrome 







The interruption of 
intoxication syndrome














Notes * – the difference between the fi rst and second 
groups is reliable (р1,3<0.05).
In particular, the normalization of blood 
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sedimentation rate during two months of intensive 
therapy was observed in 68.0% patients from the 
second group and in 31.8% patients from the fi rst 
group. At the same time, the decrease of blood 
sedimentation rate was evident more often in 
the second group as compared to the fi rst one. 
Consequently, the 2nd treatment code (AMBT + 
LIASTEN) was more effective as compared to the 
fi rst one which was proved by the fast normalization 
of general blood values and the elimination of 
intoxication syndrome. 
The microbiological research fi ndings are shown 
in Table 3. 
The monitoring of X-ray follow-up data 
proves that the faster dispersion of sites of damage 
and infi ltration was observed in the 2nd group, in 
particular, the signifi cant positive dynamics of focal 
abnormalities and infi ltration dispersion was more 
evident in the second group (28.0%) as compared 
to the fi rst one (13,6 %, р<0,05) during the fi rst two 
months of intensive therapy. The average duration of 
focal abnormalities and infi ltration dispersion was 
(6.1 ± 0.2) months in the fi rst group and (5.6 ± 0.1) 
Table 3
Frequency and terms of bacterial excretion (culturally),




Positive X-ray dynamics 























































Note* – the difference between the fi rst and second groups is reliable (р<0.05);
Table 4




Amount of examined 
patients
2
Terms of destruction cavities cicaitrization 
























Note * – the difference between the fi rst and second groups is reliable (р<0.05).
months in the second group (р<0.05). The results of 
destruction cavity cicatrization are shown in Table 4.  
The research proved the positive impact of 
the immune response modifi er LIASTEN used 
at the beginning of the intensive phase of the 
antimycobacterial therapy. In two months of the 
intensive therapy the cicatrization of the destruction 
cavity was observed in 18.2% patients from the fi rst 
group being by 2.2 times more frequent and faster 
in the patients from the second group  (40.0 %) as 
compared to the fi rst one (р<0.05-0.01). After the 
completion of the intensive phase the evidence of 
cavities was reliably less frequently observed in 
the patients treated with LIASTEN: the destruction 
was observed in 18.2% patients from the fi rst group 
being  almost by 3.6 times more frequent than in 
patients from the second group 5.0 % ( р<0.01). 
Consequently, subject to the research fi ndings the 
second treatment code is an effective one. 
The analysis of frequency and the type of residual 
effects proves that the insignifi cant abnormalities 
were observed reliably more often in the second 
group of patients cured with LIASTEN as compared 
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to the fi rst one (28.0%  versus 13.6 %, р<0.05, Table 
5).
Conclusions. The treatment of patients diagnosed 
with multi-drug resistant tuberculosis is more 
effective provided that antimycobacterial therapy is 
combined with glucosaminilmuramilpentapeptide 
(LIASTEN). In case of combining LIASTEN with 
antimycobacterial therapy abacillation was fastened 
being evident in 1,7±0,2 months, dispersion of 
focal abnormalities and infi ltration was observed in 
(1,5±0,1) months, cicatrization of destruction cavities 
was evident in (1,6±0,1) months as compared to the 
fi rst group. At the same time, the research proved that 
the average treatment duration in the intensive phase 
could be shortened to (1.9±0.3) months.
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